Whatever Jeanine was going through, even when she was going through painful surgeries, uncomfortable treatments and exhausting days in the hospital – she put others first. From bringing toys and stuffed animals to Children’s and a local women’s shelter to taking her roll as big sister to her two younger brothers very seriously and making sure they finish their homework. She had everyone’s best interest at heart. The Jeanine Sheridan Foundation strives to carry on the good that Jeanine did. You can give help in a few different ways

Monetary Donations

To give a monetary donation please contact amanda@jeaninesheridan.org

Event Participation

We hold two JSF events and participate in one as a JSF team. See our Events page for more information.

JSF Swag

On our Store page we have a number of JSF branded items including t-shirts, iphone covers and jewelry – look cute and support a great cause!

How Your Donation Helps

Explanation of graph break-down:

• Approximately 80% of JSF funds raised go to Children’s Memorial Hospital in Jeanine’s name and towards the Falk Brain Tumor Center led by Jeanine’s former Dr. Stewart Goldman. The Falk Brain Tumor Center ranks among the nation’s top programs for pediatric brain tumor diagnosis and treatment. It is one of eight members, and the only member in the Midwest, of the Pediatric Brain Tumor Consortium (PBTC), a national group helping diagnose and providing cutting-edge care for rare pediatric brain tumors. The Center also participates in numerous clinical trials sponsored by the Children’s Oncology Group (COG) and is one of five pediatric sites in the Collaborative Ependymoma Research Network. Neuro-oncologist Stewart Goldman, MD, is Principal Investigator on a Phase I/II trial to test an investigational new drug, Xerecept, in pediatric patients suffering from primary, recurrent or metastatic brain tumors. Xerecept is a new drug designed to control brain swelling in pediatric patients without the devastating side effects of steroids like the widely used agent Decadron. Xerecept has shown in Phase II and Phase III studies in adults that it may provide a safe and effective alternative to corticosteroid treatment for tumor-related brain edema and that it may also have direct anti-tumor activity. This new therapy may significantly enhance our patients’ quality of life. As one of only two sites selected for this trial, Children’s Memorial is starting to accrue patients from around the country.
  
  Dr. Goldman is participating in a PBTC Phase I study investigating the safety of a new drug, GDC-0449, to treat children with recurrent or refractory medulloblastoma. Medulloblastoma accounts for approximately 20% childhood brain tumors. While nearly 65% of these children will be cured of their disease with current standard therapy, many will suffer from long-term side effects that affect them throughout life. As a result, one goal of treatment therapy is to not only improve the prognosis but also to find treatment options that are less taxing on neurocognitive functioning. Recent advances on the molecular pathogenesis of medulloblastoma have aided in the development of new targeted therapies designed to treat this disease. The sonic hedgehog inhibitor GDC-0449 is one such drug. The sonic hedgehog signaling pathway plays a crucial role in human embryogenesis, but is largely inactive in adult tissues under normal conditions. Research has shown that overactive signaling caused by a mutation in the sonic hedgehog pathway appears to play an integral role in the initiation and propagation of some tumors of the nervous system. GDC-0449 works by blocking the pathway that continually activates tumor growth. We hope to demonstrate the therapeutic potential of sonic hedgehog inhibition in the treatment of medulloblastoma.
  
  *The only event that does not specifically benefit this cause is the “Step Up for Kids” climb the Aon Building; we raise funds as a team and all proceeds go directly to the hospital.
  
  
• 10% of funds go to patient bills – we take care of treatment, medication and other bills that are not covered by insurance in hopes to lighten the financial burden.
  
  
• The remaining 10% goes to administration costs – the board of directors does not take a salary, as stated in our foundation description. As we are a Charitable Organization we do employ the services of outside consultants required by local and Federal government to keep us running legally which at any given time includes: accountants and attorneys as well as fees associated with having a non-profit.